vs

Side-by-side financial comparison of Core Scientific, Inc. (CORZ) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

CATALYST PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($152.6M vs $79.8M, roughly 1.9× Core Scientific, Inc.). Core Scientific, Inc. runs the higher net margin — 268.5% vs 34.5%, a 234.0% gap on every dollar of revenue. On growth, CATALYST PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (7.6% vs -16.0%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $-450.8M). Over the past eight quarters, CATALYST PHARMACEUTICALS, INC.'s revenue compounded faster (24.5% CAGR vs -33.3%).

Core Scientific is a leading digital asset and high-performance computing infrastructure provider. It operates large energy-efficient data centers across North America, offering cryptocurrency mining services, colocation hosting for blockchain and AI clients, and custom high-performance computing solutions for enterprise tech segments.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CORZ vs CPRX — Head-to-Head

Bigger by revenue
CPRX
CPRX
1.9× larger
CPRX
$152.6M
$79.8M
CORZ
Growing faster (revenue YoY)
CPRX
CPRX
+23.6% gap
CPRX
7.6%
-16.0%
CORZ
Higher net margin
CORZ
CORZ
234.0% more per $
CORZ
268.5%
34.5%
CPRX
More free cash flow
CPRX
CPRX
$495.6M more FCF
CPRX
$44.9M
$-450.8M
CORZ
Faster 2-yr revenue CAGR
CPRX
CPRX
Annualised
CPRX
24.5%
-33.3%
CORZ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CORZ
CORZ
CPRX
CPRX
Revenue
$79.8M
$152.6M
Net Profit
$214.2M
$52.7M
Gross Margin
26.0%
82.9%
Operating Margin
-149.5%
40.5%
Net Margin
268.5%
34.5%
Revenue YoY
-16.0%
7.6%
Net Profit YoY
180.6%
-5.8%
EPS (diluted)
$-1.63
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORZ
CORZ
CPRX
CPRX
Q4 25
$79.8M
$152.6M
Q3 25
$81.1M
$148.4M
Q2 25
$78.6M
$146.6M
Q1 25
$79.5M
$141.4M
Q4 24
$94.9M
$141.8M
Q3 24
$95.4M
$128.7M
Q2 24
$141.1M
$122.7M
Q1 24
$179.3M
$98.5M
Net Profit
CORZ
CORZ
CPRX
CPRX
Q4 25
$214.2M
$52.7M
Q3 25
$-144.0M
$52.8M
Q2 25
$-936.8M
$52.1M
Q1 25
$576.3M
$56.7M
Q4 24
$-265.5M
$55.9M
Q3 24
$-455.3M
$43.9M
Q2 24
$-902.2M
$40.8M
Q1 24
$210.7M
$23.3M
Gross Margin
CORZ
CORZ
CPRX
CPRX
Q4 25
26.0%
82.9%
Q3 25
4.8%
84.7%
Q2 25
6.4%
85.9%
Q1 25
10.3%
87.3%
Q4 24
5.0%
84.7%
Q3 24
-0.2%
85.0%
Q2 24
27.5%
87.4%
Q1 24
43.3%
87.3%
Operating Margin
CORZ
CORZ
CPRX
CPRX
Q4 25
-149.5%
40.5%
Q3 25
-67.6%
44.7%
Q2 25
-33.4%
45.2%
Q1 25
-59.1%
44.8%
Q4 24
-41.9%
44.3%
Q3 24
-43.2%
39.6%
Q2 24
-64.3%
44.2%
Q1 24
30.8%
27.5%
Net Margin
CORZ
CORZ
CPRX
CPRX
Q4 25
268.5%
34.5%
Q3 25
-177.6%
35.6%
Q2 25
-1191.4%
35.6%
Q1 25
724.6%
40.1%
Q4 24
-279.7%
39.4%
Q3 24
-477.4%
34.1%
Q2 24
-639.4%
33.2%
Q1 24
117.5%
23.6%
EPS (diluted)
CORZ
CORZ
CPRX
CPRX
Q4 25
$-1.63
$0.40
Q3 25
$-0.45
$0.42
Q2 25
$-0.04
$0.41
Q1 25
$1.24
$0.45
Q4 24
$0.51
$0.44
Q3 24
$-1.17
$0.35
Q2 24
$-5.05
$0.33
Q1 24
$0.78
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORZ
CORZ
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$311.4M
$709.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-962.7M
$954.3M
Total Assets
$2.3B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORZ
CORZ
CPRX
CPRX
Q4 25
$311.4M
$709.2M
Q3 25
$453.4M
$689.9M
Q2 25
$581.3M
$652.8M
Q1 25
$697.9M
$580.7M
Q4 24
$836.2M
$517.6M
Q3 24
$253.0M
$442.3M
Q2 24
$96.1M
$375.7M
Q1 24
$98.1M
$310.4M
Stockholders' Equity
CORZ
CORZ
CPRX
CPRX
Q4 25
$-962.7M
$954.3M
Q3 25
$-1.3B
$920.2M
Q2 25
$-1.2B
$856.0M
Q1 25
$-308.8M
$794.3M
Q4 24
$-943.0M
$727.6M
Q3 24
$-826.7M
$660.9M
Q2 24
$-1.2B
$608.7M
Q1 24
$-318.5M
$561.4M
Total Assets
CORZ
CORZ
CPRX
CPRX
Q4 25
$2.3B
$1.1B
Q3 25
$2.2B
$1.1B
Q2 25
$1.9B
$971.9M
Q1 25
$1.5B
$908.9M
Q4 24
$1.5B
$851.4M
Q3 24
$824.6M
$772.0M
Q2 24
$664.2M
$706.4M
Q1 24
$814.0M
$646.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORZ
CORZ
CPRX
CPRX
Operating Cash FlowLast quarter
$278.3M
$44.9M
Free Cash FlowOCF − Capex
$-450.8M
$44.9M
FCF MarginFCF / Revenue
-565.1%
29.4%
Capex IntensityCapex / Revenue
914.0%
0.0%
Cash ConversionOCF / Net Profit
1.30×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$-779.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORZ
CORZ
CPRX
CPRX
Q4 25
$278.3M
$44.9M
Q3 25
$131.8M
$32.4M
Q2 25
$34.0M
$71.3M
Q1 25
$-45.0M
$60.0M
Q4 24
$42.9M
$70.9M
Q3 24
$5.7M
$72.9M
Q2 24
$1.2M
$64.1M
Q1 24
$22.2M
$31.9M
Free Cash Flow
CORZ
CORZ
CPRX
CPRX
Q4 25
$-450.8M
$44.9M
Q3 25
$-112.7M
Q2 25
$-87.3M
$71.3M
Q1 25
$-129.0M
Q4 24
$-52.1M
$70.8M
Q3 24
$-25.5M
$72.6M
Q2 24
$-1.9M
$64.1M
Q1 24
$-9.7M
$31.7M
FCF Margin
CORZ
CORZ
CPRX
CPRX
Q4 25
-565.1%
29.4%
Q3 25
-139.0%
Q2 25
-111.0%
48.6%
Q1 25
-162.2%
Q4 24
-54.8%
49.9%
Q3 24
-26.7%
56.4%
Q2 24
-1.4%
52.3%
Q1 24
-5.4%
32.2%
Capex Intensity
CORZ
CORZ
CPRX
CPRX
Q4 25
914.0%
0.0%
Q3 25
301.5%
0.0%
Q2 25
154.2%
0.0%
Q1 25
105.6%
0.0%
Q4 24
100.0%
0.1%
Q3 24
32.7%
0.2%
Q2 24
2.2%
0.0%
Q1 24
17.8%
0.2%
Cash Conversion
CORZ
CORZ
CPRX
CPRX
Q4 25
1.30×
0.85×
Q3 25
0.61×
Q2 25
1.37×
Q1 25
-0.08×
1.06×
Q4 24
1.27×
Q3 24
1.66×
Q2 24
1.57×
Q1 24
0.11×
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORZ
CORZ

Other$36.3M46%
Digital Asset Self Mining Service$31.8M40%
Colocation Service$11.6M15%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons